<DOC>
	<DOCNO>NCT01324479</DOCNO>
	<brief_summary>This study ass safety efficacy INC280 patient solid tumor refractory current treatment current standard care whose tumor dysregulation c-MET pathway .</brief_summary>
	<brief_title>Study INC280 Patients With c-MET Dependent Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Must evidence cMET dysregulation either local data result molecular prescreening evaluation . Confirmed diagnosis solid tumor . Measureable lesion . Refractory currently available treatment therapy available . 18 year old . ECOG performance status 0 , 1 , 2 . Obtained write informed consent . Additional inclusion criterion NSCLC patient EGFRwt high cMET expression : Written documentation EGFRwt NSCLC . Written documentation cMET positivity . Patients receive three prior line antineoplastic therapy NSCLC . Presence least one measurable lesion determine modified RECIST version 1.1 HCC liver dysfunction great ChildPugh A . Previous treatment cMET inhibitor HGFtargeting therapy . Symptomatic CNS metastasis neurologically unstable require increase dos steroid control CNS disease . Any CNS deficit . For patient GBM , CNS symptom grade 2 great . Subjects significant uncontrolled cardiovascular disease ( eg , uncontrolled hypertension , peripheral vascular disease , congestive heart failure , cardiac arrhythmia , acute coronary syndrome ) within 6 month start study treatment heart attack within 12 month start study treatment . Receiving antiepileptic drug know strong inducer CYP3A4 . Prior current antiangiogenic therapy patient GBM . Radiation therapy within ≤ 4 week ( &lt; 12 GBM ) prior first dose study drug limit field radiotherapy within ≤ 2 week ( &lt; 12 week GBM ) prior start study treatment . Any persistent side effect prior radiotherapy must resolve ≤ Grade 1 prior first dose study drug . Additional exclusion criterion NSCLC patient EGFRwt high cMET expression : Patients receive three prior line antineoplastic therapy Any unresolved toxicity ( CTCAE grade &gt; 1 ) previous anticancer therapy radiotherapy , except alopecia Patients receive anticancer therapy within follow time frame prior first dose study treatment : Conventional cytotoxic chemotherapy : ≤4 week ( ≤6 week nitrosoureas mitomycinC ) Biologic therapy ( e.g. , antibody ) : ≤4 week Noncytotoxic small molecule therapeutic : ≤5 halflives ≤2 week ( whichever longer ) Other investigational agent : ≤4 week Radiation therapy ( palliative setting allow . ) : ≤4 week Major surgery : ≤2 week Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non-small cell lung cancer ,</keyword>
	<keyword>hepatocellular ,</keyword>
	<keyword>gastric ,</keyword>
	<keyword>renal cell ,</keyword>
	<keyword>c-MET ,</keyword>
	<keyword>refractory ,</keyword>
	<keyword>glioblastoma ,</keyword>
	<keyword>breast ,</keyword>
	<keyword>nasopharyngeal ,</keyword>
	<keyword>confirm evidence c-MET dysregulation</keyword>
</DOC>